Lexicon Pharmaceuticals (LXRX) Stock: Buy, Sell, or Hold?
LXRX - Lexicon Pharmaceuticals, Inc.
$1.43
-0.06 (-4.36%)
▼
5d:
-6.25%
30d:
-23.39%
90d:
-36.1%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 05, 2026
12d
Get Alerted When LXRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: LXRX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: LXRX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: LXRX is currently trading at $1.43, which is considered oversold relative to its 30-day fair value range of $1.59 to $1.99.
Technical Outlook: Technically, LXRX is in a strong uptrend. The price is currently testing key support at $1.48. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: LXRX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.55 (+205.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LXRX is in a strong uptrend. The price is currently testing key support at $1.48. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: LXRX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.55 (+205.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.59 -
$1.99
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.4%)
- BULLISH: Trading 205.1% below Wall St target ($4.55)
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.59 -
$1.99
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.48
Resistance Level
$1.77
Current Trend
Strong Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.82
Wall Street Target
$4.55
(+205.1%)
Revenue Growth (YoY)
-97.6%
Earnings Growth (YoY)
-63.4%
Profit Margin
-147.4%
Share & Embed Analysis
Last updated: October 23, 2026 12:32 PM ET
Data refreshes hourly during market hours. Next update: 1:32 PM
Data refreshes hourly during market hours. Next update: 1:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LXRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 58 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 53 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 64 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 48 HOLD |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 59 HOLD |